Medexus Completes Enrollment in Phase IV Clinical Trial of IXINITY^® Targeting Label Expansion for Pediatric Hemophilia B Patients

Medexus Pharmaceuticals, Inc. announced that is has completed enrollment in its Phase IV Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients.